bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Abroad (travel likely)Recruiting

Conditions

Liver Diseases · Hepatocellular Carcinoma · Immunotherapy · Camrelizumab · Lenvatinib

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
Contact: Study coordinator (Qunfang Zhou, MD) · zhouqun988509@163.com · 86 19868000115

Study leads

Zhimei Hunag, MD
Study Director
Sun Yat-sen University
Jinhua Huang, Profession
Study Director
Sun Yat-sen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma

Hepatocellular Carcinoma · Immunotherapy

Abroad (travel likely)Recruiting

Hangzhou, China

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma · Conversion Therapy

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular Carcinoma · Local Advanced Hepatocellular Carcinoma · Alpha-fetoprotein (AFP)-Producing Gastric Cancer

Abroad (travel likely)RecruitingPHASE1

Goodyear, United States · Duarte, United States

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bengbu, China · Hefei, China